Perspective Therapeutics, Inc. (NYSE:CATX) Receives $15.14 Consensus PT from Analysts

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $15.14.

Several equities research analysts have commented on CATX shares. Oppenheimer cut their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $24.00 to $5.00 in a research note on Monday, November 25th. UBS Group started coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Finally, Royal Bank of Canada lowered their price target on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research report on Monday, November 25th.

Perspective Therapeutics Trading Down 3.0 %

NYSE CATX opened at $3.19 on Wednesday. Perspective Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $19.05. The stock has a 50-day simple moving average of $6.86 and a two-hundred day simple moving average of $10.76.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million during the quarter. On average, research analysts anticipate that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, CFO Jonathan Robert Hunt bought 12,829 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were purchased at an average price of $3.82 per share, with a total value of $49,006.78. Following the completion of the acquisition, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at $186,416. This represents a 35.66 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Johan M. Spoor purchased 8,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were acquired at an average cost of $3.77 per share, with a total value of $30,160.00. Following the completion of the acquisition, the chief executive officer now directly owns 36,257 shares in the company, valued at $136,688.89. The trade was a 28.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 67,570 shares of company stock valued at $256,789 in the last quarter. Corporate insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. Bank of New York Mellon Corp grew its position in shares of Perspective Therapeutics by 214.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after buying an additional 93,548 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of Perspective Therapeutics during the second quarter worth about $630,000. Victory Capital Management Inc. acquired a new stake in shares of Perspective Therapeutics during the second quarter worth about $117,000. ClariVest Asset Management LLC purchased a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at about $540,000. Finally, Sykon Capital LLC boosted its position in shares of Perspective Therapeutics by 4.7% in the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after purchasing an additional 1,717 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.